Thomas Ly
5 Papers
1 Citations
Thomas Ly is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study
Farhad Ravandi,Asad Bashey,James M. Foran,Wendy Stock,Raya Mawad,William Blum,M. Wayne Saville,Chelsea M. Johnson,K. Gary Vanasse,Thomas Ly,Hagop M. Kantarjian,Bhavana Bhatnagar,Koichi Takahashi,Alice S. Mims +13 more
TL;DR: The primary objective was to estimate the maximum tolerated dose (MTD) or recommended dose and schedule of XmAb14045, a potent bispecific antibody targeting both CD123 and CD3 that stimulates targeted T cell-mediated killing of CD123-expressing cells, regardless of T cell antigen specificity.
63
Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia
Krish Patel,Jean-Marie Michot,Asher Chanan-Khan,Gilles Salles,Guillaume Cartron,Frederic Peyrade,Reda Bouabdallah,Erin Reid,Sheeba K. Thomas,William G. Wierda,David Liebowitz,John M. Pagel,Vincent Ribrag,M. Wayne Saville,Chelsea M. Johnson,Thomas Ly,Tycel Phillips +16 more
TL;DR: This research highlights the need to understand more fully the role of emotion in the decision-making process and the role that emotion plays in the development of new treatments.
29
Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies
Amitkumar Mehta,Umar Farooq,Andy I. Chen,Joseph P. McGuirk,Thomas Ly,Lilly Wong,Sarah Cooley,Bahram Valamehr,Rebecca Elstrom,Yu-Waye Chu,Jae H. Park +10 more
TL;DR: The first clinical trial of an iPSC-derived CAR T-cell product candidate, FT819, was evaluated in patients with relapsed/refractory (R/R) B-cell lymphomas (BCLs), chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia (B-ALL) as discussed by the authors .
27
Interim Phase I Clinical Data of FT576 As Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma
Binod Dhakal,Jesus G. Berdeja,Tara K. Gregory,Thomas Ly,Cara Bickers,Xingyue Zong,Lilly Wong,Jode P Goodridge,Sarah Cooley,Bahram Valamehr,Yu-Waye Chu,John Byon,Rafat Abonour +12 more
TL;DR: Munshi et al. as discussed by the authors proposed a multiplexed-engineered BCMA CAR T-cell therapy for multiple myeloma (R/R) patients, which can be used as a renewable source for the mass production of off-the-shelf NK cells.
23
A Phase I Study of FT538, an Off-the-Shelf, Multiplexed-Engineered, iPSC-Derived NK Cell Therapy in Combination with Daratumumab in Relapsed/Refractory Multiple Myeloma
Mark B. Juckett,Sham Mailankody,Alireza Eghtedar,Cara Bickers,Xingyue Zong,Lilly Wong,Thomas Ly,John Byon,Sarah Cooley,Bahram Valamehr,Yu-Waye Chu,Ravi Vij +11 more
TL;DR: In this paper , an off-the-shelf, multiplexed-engineered allogeneic natural killer (NK) cell therapy was used to treat relapsed/refractory (R/R) multiple myeloma (MM) patients.
5